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Background: The clinical course of cutaneous melanoma (CM) can differ significantly for patients with identical
stages of disease, defined clinico-pathologically, and no molecular markers differentiate patients with such a
diverse prognosis. This study aimed to define the prognostic value of whole genome DNA methylation
profiles in stage III CM.
Methods: Genome-wide methylation profiles were evaluated by the Illumina Human Methylation 27 BeadChip
assay in short-term neoplastic cell cultures from 45 stage IIIC CM patients. Unsupervised K-means partitioning
clustering was exploited to sort patients into 2 groups based on their methylation profiles. Methylation
patterns related to the discovered groups were determined using the nearest shrunken centroid classification
algorithm. The impact of genome-wide methylation patterns on overall survival (OS) was assessed using Cox
regression and Kaplan-Meier analyses.
Results: Unsupervised K-means partitioning by whole genome methylation profiles identified classes with
significantly different OS in stage IIIC CM patients. Patients with a “favorable” methylation profile had
increased OS (P = 0.001, log-rank = 10.2) by Kaplan-Meier analysis. Median OS of stage IIIC patients with a
“favorable” vs. “unfavorable” methylation profile were 31.5 and 10.4 months, respectively. The 5 year OS for
stage IIIC patients with a “favorable” methylation profile was 41.2% as compared to 0% for patients with an
“unfavorable” methylation profile. Among the variables examined by multivariate Cox regression analysis,
classification defined by methylation profile was the only predictor of OS (Hazard Ratio = 2.41, for
“unfavorable” methylation profile; 95% Confidence Interval: 1.02-5.70; P = 0.045). A 17 gene methylation
signature able to correctly assign prognosis (overall error rate = 0) in stage IIIC patients on the basis of distinct
methylation-defined groups was also identified.
Conclusions: A discrete whole-genome methylation signature has been identified as molecular marker of
prognosis for stage IIIC CM patients. Its use in daily practice is foreseeable, and promises to refine the
comprehensive clinical management of stage III CM patients.
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Cutaneous melanoma (CM) is an aggressive neoplasm
with growing incidence and mortality rates in industria-
lized countries, and the leading cause of skin cancer-
related deaths worldwide [1]. At present, the only estab-
lished prognosticator of 5-year survival, used clinically
for routine therapy and for clinical trials, is the clinico-
pathological stage of disease. Overall survival (OS) rates
range from 95% for stage I to 7% for stage IV patients
[2,3]. However, the clinical course of CM within clinico-
pathological stages also differs radically, and the lack of
prognostic markers has impaired our ability to identify
subjects with highly aggressive as opposed to indolent
course of disease [4].
Methylation of genomic DNA in mammals occurs at the
5 C-position of cytosine in the context of CpG dinucleo-
tides, resulting in gene silencing through different mechan-
isms [5]. Alterations in genomic DNA methylation
represent a hallmark of cancer and actively contribute to
cancer development and progression through inactivation
of tumor suppressor genes (TSG) by aberrant promoter
hypermethylation [6]. In particular, epigenetic alterations
have emerged as important factors in tumor progression in
CM, as demonstrated by the growing list of genes that are
transcriptionally inactivated by aberrant DNA hypermethy-
lation in this neoplasia, affecting virtually every pathway
known to be important for its biology [5]. The increasing
role of aberrant methylation in CM biology strongly sug-
gests the potential of methylation markers as indicators of
disease prognosis. Along this line, preliminary studies high-
light a possible prognostic role of the methylation status of
selected genes in CM patients. Among these, PTEN methy-
lation emerged as an independent negative prognostic fac-
tor in a cohort of 230 patients with stage 0 to IV of disease;
however, it did not outperform traditional markers of
tumor thickness and ulceration [7]. Similarly, methylation
of the TSG TSLC1 was found to be significantly increased
in advancing CM stages, where it was associated with
reduced disease-related survival [8]. Furthermore,
methylation of the ‘methylated in tumors’ (MINT)
locus 31 was shown to be significantly associated with
advancing clinical stage among 107 stage I to IV CM
patients, predicting improved disease-free survival and
OS of the 25 stage III patients analyzed [9]. While
these data are encouraging, studies reported to date
have several limitations, including: i) investigation of
only single/few genes; ii); a priori selection of genes
to be evaluated; iii) analysis of CM patients popula-
tions with highly heterogeneous stages of disease. To
address these issues, in an initial search for the prog-
nostic significance of DNA methylation of CM cells,
we have recently demonstrated that global genomic
DNA hypermethylation, as evaluated on the Long
Interspersed Nucleotide Element-1 (LINE-1) repetitivesequences, is associated with significantly reduced OS
among stage IIIC CM patients [10].
Based on these promising findings, this study aimed to
explore whether whole-genome methylation profiles may
account for the differential prognosis of CM patients
within an identical clinico-pathological stage of disease.
To this end, neoplastic cells from 45 stage IIIC CM
patients were analyzed for their genome-wide methyla-
tion profiles by the Infinium HumanMethylation27
BeadChips, which allow interrogation of methylation for
over 14,000 genes. Autologous short-term neoplastic cell
cultures were utilized instead of tumor tissues to overcome
alterations in the evaluation of CM-specific genomic
methylation profiles due to the presence of contaminating
normal cells.
The results generated demonstrate that whole-genome
methylation profiling is a powerful tool to identify CM
patients with a significantly different prognosis, and that a
methylation signature of 17 genes can be utilized to assign
CM patients to distinct prognostic groups.
Methods
Patients and cell cultures
Short-term cell cultures were established from meta-
static lesions removed surgically from consecutive CM
patients referred to the National Cancer Institute of
Aviano (Italy) for stage III surgery from 1991 to 2007,
as previously described [11]. Patients provided written
informed consent as per Italian regulations. Success
rate in establishing autologous tumor cell cultures
from neoplastic tissues was approximately 30%. The
micrometastatic nature of lymph-node tumor tissues
from AJCC stage IIIA patients precluded their use for
cell culture generation, while short-term CM cultures
were available from 13 stage IIIB patients, and so
were excluded from the study. Thus, the planned
investigations were conducted on short-term cultures
generated from a total of 45 CM patients, classified
as AJCC stage IIIC, who received highly heteroge-
neous treatments for their disease, including chemo-
therapy with different agents, immunotherapy, and
radiotherapy. Forty-three cell cultures were derived
from metastatic lymph-nodes ad 2 from subcutaneous
loco-regional lesions. Short-term CM cell cultures
were grown in RPMI 1640 Medium supplemented
with 20% heat-inactivated fetal calf serum and
2 mM L-glutamine (Biochrome KG, Berlin, Germany).
To minimize alterations potentially arising with
extended in vitro culturing, all cell cultures were uti-
lized for molecular assays at the 6th ex vivo passage.
Cell cultures were confirmed to contain ≥ 95% CM
cells as determined by indirect immunofluorescence
staining followed by flow cytometric analyses for
melanoma-associated antigens (data not shown).
Table 1 Sequences of primers used for qMSP and
qRT-PCR assays
qMSP
GENE Primer sequence1 Amplicon
size (bp)2
SLC6A11 MF: TGTTTAGGGTTGGGAAGAAGTTAC 128
MR: ATCGCAATAAACTAAAAAACCTACG
UF: TGTTTAGGGTTGGGAAGAAGTTAT 133
UR: AATAAATCACAATAAACTAAAAAACCTACA
TUB MF: TGGTTGTTAGTTTGATTGTTGTTAC3 96
MR: AAAACCTATTAAAATTCCCTATATTCG
UF: GTGGTTGTTAGTTTGATTGTTGTTAT 97
UR: CTAAAACCTATTAAAATTCCCTATATTCA
ALOX12B MF: TTCTCTTACCTACCTTAAACCTTCG 152
MR: TGAGATGGAGTTTCGTGTTTTC
UF: TTCTCTTACCTACCTTAAACCTTCA 154
UR: AGTGAGATGGAGTTTTGTGTTTTT
WNT10B MF: TGGGGTGTATAGGTAAAGGTAAATC 91
MR: GAAAATAAATCAAACGAAAACACG
UF: TGGGGTGTATAGGTAAAGGTAAATT 93
UR: TCAAAAATAAATCAAACAAAAACACA
qRT-PCR
GENE Primer sequence Amplicon
size (bp)
ALOX12B F: ACCCGAGGGCAAGATGAT 74
R: GCAGGAAGATGGGGCAAT
SLC6A11 F: AGGGGGTACCCATTGCTG 65
R: CTTGGGGTACGCAATAAAGG
TUB F: TCCGACTGGATTCCCTACAG 109
R: GGCGCTTCTTCTTCTGCTT
WNT10B F: GCGAATCCACAACAACAGG 107
R: TCCAGCATGTCTTGAACTGG
1 MF, methylated forward primer; MR, methylated reverse primer; UF,
unmethylated forward primer; UR, unmethylated reverse primer; F, forward
primer; R, reverse primer.
2 Size of the amplification product in base pairs.
3 Underlined text represent locked nucleic acid (LNA)-modified nucleotides.
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Genomic DNA was extracted from short-term cultures
of CM cells by a standard proteinase K protocol [12].
The 45 samples under analysis were evaluated for
genome-wide promoter methylation at the Cluster in
Biomedicine scrl (Trieste, Italy) using the Illumina Infi-
nium HumanMethylation27 Bead array (Illumina Inc,
San Diego, CA). Analyses were conducted on 500 ng of
genomic DNA, and were performed as per Illumina
protocol. The arrays were imaged using a BeadArray™
Reader. Image processing and intensity data extraction
were performed according to Illumina's instructions.
The methylation status of a specifc CpG site was calcu-
lated from the intensity of the methylated (M)- and
unmethylated (U)-specific beads, as the ratio of fluores-
cent signals: β=Max(M,0)/[Max(M,0) +Max(U,0)]. DNA
methylation β values are continuous variables between 0,
no methylation, and 1, completely methylated.
qMSP analyses
Genomic DNA was subjected to modification with so-
dium bisulfite using the EZ DNA Methylation-Gold Kit
(Zymo Research, Orange, CA, USA). Primers for the
analysis of the methylation status of ALOX12B,
SLC6A11, TUB, and WNT10B, were designed using the
free on-line software MethPrimer [13], and are reported
in the Table 1. SYBR green qMSP reactions were per-
formed with methylated- or unmethylated-specific pri-
mer pairs on 2 μl of bisulfite-modified genomic DNA.
The copy number of methylated or unmethylated
sequences for each target gene were established by ex-
trapolation from the standard curves. The % of methyla-
tion was defined as the ratio between methylated
molecules and the sum of methylated and unmethylated
molecules.
qRT-PCR analyses
Real-time qRT-PCR analyses were performed as previ-
ously described [12]. Primers sets used are listed in
Table 1. The copy number of target genes and of the
reference gene β-actin were established in each sample
by extrapolation from the standard curves. The number
of target gene cDNA molecules in each sample was nor-
malized to the number of cDNA molecules of β-actin.
Statistical analysis
Statistical analyses were performed using the R statistical
environment (http://www.R-project.org) and bioconductor
packages (http://www.bioconductor.org). We used the
methylumi package for importing and pre-processing the
methylation data, the survival package for Kaplan-Meier
estimates, and the pamr package for the shrunken centroid
supervised analysis. The methylation data from the Illumina
Beadstudio software were imported in R, checked forquality and normalized. K-means partitioning clustering
was used to divide the data into 2 groups. The primary
objective was to determine differences in OS between
the patient groups defined by K-means partitioning.
Survival time was calculated in months from the date
of stage IIIC diagnosis until the date of death.
According with the specific goals of the analysis, we
did not classify the deaths considering their cause.
Patients were censored at the last follow-up date or
the last date the patient was known to be alive. Median
survival duration was determined by the Kaplan-Meier
method [14]. Cumulative survival was evaluated using the
log-rank test. Cox proportional hazard method [15] was
Table 2 Characteristics of the 45 AJCC stage IIIC
melanoma patients
Variable n. patients %
Age, years
Median 52
Range 29-83
Gender
Male 28 62.2
Female 17 37.8
Localization of primary tumor
extremities 16 35.6
trunk 24 53.3
head & neck 2 4.4
NA1 3 6.7
Breslow thickness of primary tumor
≤2.0 mm 13 28.9
>2.0 mm 25 55.6
NA 7 15.6
Clark level of primary tumor
1-3 13 28.9
4-5 26 57.8
NA 6 13.3
Ulceration of primary tumor
No 10 22.2
Yes 33 73.3
NA 2 4.4
N. lymph nodes involved
1 9 20
>1 35 77.8
NA 1 2.2
LDH2
Low3 31 68.9
High 11 24.4
NA 3 6.7
BRAFV600E
mutated 25 55.6
wild-type 15 33.3
NA 5 11.1
LINE-14
hypomethylated 22 49
hypermethylated 23 51
1 NA, not available.
2 LDH, lactate dehydrogenase.
3 low LDH is established as LDH values ≤ 0.8 times the upper limit of normal;
high LDH is defined as LDH values > 0.8 times the upper limit of normal.
4 extent of methylation of LINE-1 was evaluated by pyrosequencing and
defined as hypomethylated or hypermethylated depending on the
methylation level being < or≥ the median of the population, respectively.
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methylation profiles on survival and results were presented
as HR with corresponding 95% CI. Variables significantly
associated with OS in univariate analysis were included in a
multivariate model.
Methylation patterns (signatures) of the discovered
groups were determined using the nearest shrunken cen-
troid classification algorithm (PAM). The threshold for
balancing between the number of sample correctly clas-
sified and the subset of features representing the methy-
lation patterns was determined by cross-validation [16].
The correlation between methylation values from Illu-
mina Infinium and qMSP assays, as well as between
gene methylation and mRNA expression, were evaluated
by the Spearman’s rank correlation test. The genome-
wide methylation profile of each patient was also sum-
marized with a “methylation score” as follows: methyla-
tion for each gene among the patients was standardized
by the Z score method, each patient was then assigned a
“methylation score” consisting of the average of Z scores
of all genes. Differences in “methylation score” between
k-means defined patient groups were evaluated by Stu-
dent’sT test. Reported P values are two sided and values
<0.05 were considered to be statistically significant.
Results
Patients
The study was conducted on CM patients who under-
went radical lymph node dissection for stage III disease
at the Centro di Riferimento Oncologico National Can-
cer Institute between 1991 and 2007. Patients diagnosed
with a stage IIIC disease, and for whom a short-term cell
culture had been successfully generated from the surgi-
cally removed autologous neoplastic tissue, were
included. Table 2 summarizes the 45 patients under
study and their clinico-pathologic characteristics at
presentation.
Unsupervised analysis of whole-genome methylation
profiles and survival analysis
Genome-wide gene methylation profiles were evaluated
in the 45 short-term CM cell cultures under study using
the Illumina HumanMethylation27 Bead-Chip whole-
genome assay, which interrogates 27,578 CpG sites, cor-
responding to 14,495 genes. Patients were divided into 2
subgroups, according to their whole genome methylation
profile, by the k-means clustering method (Figure 1).
The subgroups generated included 33 and 12 patients
(Figure 1).
“Methylation scores” were calculated for each patient
describing the methylation density of the genome, with
values > 0 representing methylation above the popula-
tion’s mean. Noteworthy, the 2 k-means-defined groups
differed significantly (p < 0.001) in their global levels of
Figure 1 Groups of stage IIIC CM patients identified by whole-genome methylation profiling. Genome-wide DNA methylation profile was
evaluated by Illumina HumanMethylation27 Bead-Chip whole-genome assay in short-term cultures of CM cells generated from neoplastic lesions
of 45 stage IIIC CM patients. Cells were analyzed at 6th in vitro passage. Patients were divided into 2 classes (LM and HM) based on the whole
genome methylation profile of their tumor cells through the k-means algorithm. Panel a, the whole genome methylation profiles in the patients’
population have been reported as a heatmap. Patient identifier numbers and the k-means-defined groups have been reported on top of the
heatmap. Each color patch represents the methylation level of one gene in each patient, with a continuum of methylation levels from dark blue
(completely unmethylated, β= 0) to dark red (completely methylated, β= 1). Panel b, the genome-wide methylation profile of each patient was
summarized by the “methylation score”, where “methylation scores”> and< 0 represent methylation above and below the population’s mean,
respectively. Separate box plots have been generated for the LM and HM whole methylome defined patients’ groups. Black horizontal bars
represent the median values of “methylation score” for each group. *, P = 0.001 as evaluated by Student’s T test.
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−0.2 for the 33 patient group as compared to 0.46 for the
12 patient group (Figure 1). Accordingly, groups were re-
ferred to as low-methylation (LM) and high-methylation
(HM), respectively.
The impact of the genome-wide methylation profile-
based classification on OS was assessed by Kaplan-Meier
analysis. Results demonstrated a significant survival ad-
vantage for patients classified as LM as compared to
HM (P = 0.001, log-rank = 10.9), with an increased
median OS of 31.5 months for LM (95% Confidence
Interval (CI): 13.12-inf ) compared to 10.4 months
(95% CI: 5.29-inf ) for HM patients (Figure 2). The
5 year OS of patients classified as LM and HM were
41.2% and 0%, respectively.
Cox univariate analysis was carried out to identify pa-
tient characteristics and clinico-pathologic factors that
predict OS. Among the range of factors examined, in-
cluding age, gender, localization, Breslow thickness,
Clark level and ulceration of primary tumor, as well as
number of lymph nodes involved, pre-operative lactate
dehydrogenase, BRAFV600E mutation status, and LINE-1methylation, only classification by the genome-wide
methylation profiles (Hazard Ratio (HR) =3.3 for group
HM vs. LM; 95% CI: 1.56-6.99; P=0.001; Table 3) and
LINE-1methylation (HR=2.52 for LINE-1 hypermethylated
vs hypomethylated group; 95% CI: 1.21-5.26; P=0.01;
Table 3) were associated with statistically significant differ-
ences in OS. When these 2 variables were included in a
multivariate Cox model, only whole-methylome defined
K-means classification retained a significant impact on
OS (Table 3).
Despite the above reported impact on OS, χ squared
analyses did not show any significant association be-
tween methylation profiles and metastatic patterns, with
a particular focus on the development of brain metastasis
(p = 0.29).
Identification of the methylation signature of CM patient
subgroups with different prognosis
To define the methylation signature representing the
minimal number of methylation markers characterizing
LM and HM patient groups, we applied the “nearest
shrunken centroid” algorithm [16] (Figure 3). A
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Figure 2 Kaplan-Meier analysis of stage IIIC CM patients survival according to genome-wide methylation profiles. Genome-wide DNA
methylation profile was evaluated by Illumina HumanMethylation27 Bead-Chip whole-genome assay in short-term cultures of CM cells generated
from neoplastic lesions of 45 stage IIIC CM patients. Cells were analyzed at 6th in vitro passage. Patients were divided into 2 classes (LM and HM)
based on the whole genome methylation profile of their tumor cells through the k-means algorithm. Kaplan-Meier function for OS was calculated
for stage IIIC CM patients either unstratified (a), or stratified according to k-means-defined methylation classes (b). Dashed and solid lines refer to
patients’ groups LM and HM, respectively. Vertical bars in the Kaplan-Meier curves represent censored patients. Cumulative survival by k-means-
defined methylation group was evaluated using the Log-Rank test, reported P values were two sided.
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that allowed to correctly sort stage IIIC patients into
groups LM and HM (overall error rate = 0), was identi-
fied. A dramatic difference in the methylation status of
the genes included in the signature is evident between
the good prognosis LM and the bad prognosis HM
groups of patients (Figure 3).
Validation of microarray data
Array-based methylation profiling was validated on the
short-term CM cell cultures under analysis using quanti-
tative Methylation-Specific PCR (qMSP) for selected
genes composing the 17-gene methylation signature.
Genes were selected among those having the highest im-
pact on the classification task, which could be identifiedTable 3 Univariate and multivariate analysis of the influence
CM patients
Univariate
Group1 # events/# patients2 HR3
LM 20/33 15
HM 12/12 3.30
LINE-1 hypomethylated 12/22 1
LINE-1 hypermethylated 20/23 2.52
1 Patients were divided by the k-means clustering algorithm in 2 groups (LM, HM),
being < (hypomethylated) or≥ (hypermethylated) the median value of the populatio
2 number of patients who died (# events) and total number of patients in the group
3 Cox proportional hazard method was used to evaluate the effect of the examined
corresponding 95% Confidence Intervals (CI);
4 a multivariate Cox proportional hazard model was constructed for OS, including k
methylation;
5 set as reference.by their positioning at the top of the shrunken centroids
graph (Figure 3a). Spearman’s rank correlation identified
a highly significant (p ≤ 10-4) positive correlation be-
tween methylation values determined by the Illumina
Infinium platform and those defined by qMSP, for all of
the 4 genes under analysis (WNT10B, TUB, ALOX12B,
SLC6A11; Figure 4). Coefficients of correlation ranged
from 0.541 to 0.791, for WNT10B and ALOX12B, re-
spectively (Figure 4).
To confirm the tumor-specificity of the methylation
patterns identified, qMSP assays were also performed on
commercially available epidermal melanocytes and nor-
mal peripheral blood mononuclear cells from healthy
subjects and selected patients under study. Results
demonstrated an invariably unmethylated (WNT10B) orof genome-wide methylation profiles on OS of stage III
Multivariate
95% CI P HR4 95% CI P
1
1.56-6.99 0.001 2.41 1.02-5.70 0.045
1
1.21-5.26 0.01 1.76 0.75-4.13 0.20
according to their genome-wide methylation profile, or by LINE-1 methylation
n;
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Figure 3 Prognostic methylation signatures identified by the “nearest shrunken centroid” algorithm in stage IIIC CM patients.
Pre-processed genome-wide methylation data from stage IIIC CM patients under study was analyzed through nearest shrunken centroids
algorithm to identify genes best characterizing the k-means defined prognostic methylation groups. Panel a, Shrunken differences for the 17
methylation markers, having at least 1 non-zero difference, selected as signature for LM (blue) and HM (red) groups. Lines to the left indicate
relatively reduced levels of methylation; lines to the right indicate relatively increased levels of methylation. Genes defining the signature have
been reported as Gene Symbol on the left of the panel. Duplicate Gene Symbol entries refer to methylation data read for the same gene from
different probes. Panel b, the methylation values of the 17 genes composing the methylation signature in the patients’ population have been
reported as a heatmap. Genes defining the signature have been reported as Gene Symbol on the right of the heatmap, while patient identifier
numbers and the k-means-defined groups have been reported on foot of the heatmap. Duplicate Gene Symbol entries refer to methylation data
read for the same gene from different probes. Each color patch represents the methylation level of one gene in each patient, with a continuum
of methylation levels from dark blue (completely unmethylated, β= 0) to dark red (completely methylated, β= 1).
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normal samples (data not shown) as compared to the
variable levels of methylation observed in tumor cells
(Figure 4).
Correlation with gene expression
The differential gene methylation patterns observed
among CM patients could contribute to differential sur-
vival through altered expression of the respective genes.
To initially evaluate this aspect, the expression of
selected genes included in the 17-gene methylation sig-
nature was evaluated by quantitative RT-PCR (qRT-
PCR) in the 45 short-term CM cell cultures under study.Low, and somewhat heterogeneous levels of WNT10B,
TUB, ALOX12B, and SLC6A11 mRNA were observed
(Figure 4). A significant (p < 0.05) correlation was found
between expression and gene methylation for WNT10B
and ALOX12B, though Rho values were < 0.5.
Discussion
In this study we demonstrate that the genome-wide
DNA methylation profile of tumor cells from CM
patients with nodal metastases is a significant predictor
of OS within stage IIIC. This finding provides the first
evidence that genome-wide methylation profiles can
serve as molecular markers of prognosis for CM patients
Table 4 Genes composing the prognostic methylation
signature for the 45 stage IIIC CM patients
TargetID1 GENE ID2 SYMBOL3 Distance to TSS4 CPG ISLAND5
cg00498305 6571 SLC18A2 480 TRUE
cg01333788 2709 GJB5 93 FALSE
cg02064402 348932 SLC6A18 249 FALSE
cg02415431 3543 IGLL1 760 FALSE
cg03742272 242 ALOX12B 316 FALSE
cg05164634 7480 WNT10B 995 TRUE
cg05492113 7275 TUB 152 FALSE
cg07039113 6280 S100A9 1317 FALSE
cg08929103 1394 CRHR1 1331 FALSE
cg09196959 135644 TRIM40 70 FALSE
cg09395732 6538 SLC6A11 461 TRUE
cg14236389 284756 FLJ33860 58 TRUE
cg14578030 2249 FGF4 1212 FALSE
cg16139316 6280 S100A9 428 FALSE
cg22088368 339669 MGC35206 1049 FALSE
cg24076884 56134 PCDHAC2 569 TRUE
cg26424956 2914 GRM4 83 FALSE
1 Illumina unique probe identifier;
2 Unique NCBI's Entrez Gene record (gene identifier) for the gene;
3 unique gene symbol as established by the HUGO Gene Nomenclature
Committee;
4 distance in base pairs from the putative transcription start site of the gene;
5 location of the assayed CpG site in a region fulfilling the definition of CpG
island.
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tiple adjuvant trials.
Promoter hypermethylation has been proposed to
have an important impact on tumor biology through
the silencing of TSG and the alteration of virtually
every cellular pathway relevant to CM development
and progression [5]. Accordingly, initial studies evaluated
the status of specific genes known to be methylated in
cancer, and showed an association of promoter hyper-
methylation and advancing tumor stage, reduced disease-
related survival and/or OS in CM patients [7,8]. These
studies relied on the a priori selection of few genes and
generally enrolled CM patients from highly heterogeneous
disease stage-groupings.
The results of the present study demonstrate the adverse
prognostic impact of genome-wide hypermethylated pro-
files in relation to OS, and more importantly, for patients
within a single stage sub-grouping of disease, have shown
remarkable prognostic significance for the methylation pro-
file. This observation strongly supports the notion that the
constitutive methylation profile of cancer cells is intimately
linked to the behavior of the tumor, and drives differing
outcomes of disease. This concept is further strengthened
by the discovery that, among all clinico-pathological and
molecular factors examined, only those linked to genome-wide methylation were significantly associated with
OS among CM patients analyzed. In this context, the
multivariate Cox model identified whole-methylome-
profile-defined classification as the most robust prognostic
marker, suggesting its superior ability in the identification
of biologically relevant methylation backgrounds as
compared to LINE-1 methylation [10].
Genome-wide methylation profiles could be recapitu-
lated using a 17-gene signature, which was sufficient to
correctly assign CM patients to the identified prognostic
groups. Intriguingly, none of the genes composing the
signature has been previously reported to be methylated
in CM, demonstrating that “unbiased” methylation pro-
filing represents an appropriate and possibly more ef-
fective tool for the identification of novel prognostic/
predictive epigenetic markers in human cancer.
The mechanisms through which the different methy-
lome profiles affect the survival of CM patients remain to
be defined. A direct contribution of the products of the 17
signature genes is unlikely since no meaningful association
was observed between methylation and expression of ana-
lyzed genes (Figure 4). The methylation signature, thus,
appears as an effective bona fide prognostic marker,
accounting for the overall methylation profile of tumor
cells, without a direct impact on tumor biology that can
presently be defined. A similar observation was recently
reported by Tanemura et al. [9] who evidenced a signifi-
cant positive association of MINT31 hypermethylation
and improved disease-free survival and OS in stage III
CM patients. Since no established product is known for
MINT31 locus, the authors suggested that the methylation
status of the locus could be linked to the activation status
of additional genes yet to be identified [9]. This appears to
be true, more in general, for the widely described
phenomenon of the CpG island methylator phenotype
(CIMP), which has been described in several tumor types,
and refers to a high frequency of concomitant aberrant
hypermethylation of different genes and/or chromosomal
loci [17]. Indeed, presence of CIMP, rather than account-
ing for the transcriptional suppression of the specific
genes tested, identifies tumors that have a higher propen-
sity to manifest genome-wide hypermethylation, and thus
are more likely to inactivate genes critical for tumor pro-
gression and response to therapy, leading to a worst prog-
nosis [18]. In line with this notion, functional enrichment
analysis of the genes that were significantly differentially
methylated between LM and HM groups revealed a per-
turbation of several biological pathways, including cyto-
kine signaling, cell adhesion, drug and retinol metabolism,
and natural killer cell mediated cytotoxicity (Additional
file 1). Thus, the global alteration of these pathways could
account for the different OS of CM patients bearing differ-
ent methylomes. Intriguingly, biological processes
involved in immune response are highly represented in
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Figure 4 Validation of microarray data. Short-term cultures of CM cells generated from neoplastic lesions of 45 stage IIIC melanoma patients
were evaluated for WNT10B, TUB, ALOX12B and SLC6A11 methylation and mRNA expression by qMSP and qRT-PCR analyses, respectively. All cells
were analyzed at 6th in vitro passage. For each gene, the % of methylation measured by qMSP was defined as the ratio between methylated
gene molecules and the sum of methylated and unmethylated gene molecules. Level of gene expression is reported as number of molecules of
the target gene normalized to the number of molecules of the housekeeping gene β-actin. Panel a, Correlation between % methylation defined
by qMSP and β-values defined by the Illumina HumanMethylation27 Bead-Chip assay was evaluated for each gene through the Spearman’s rank
correlation test. Reported P values are two sided. Panel b, Correlation between methylation and mRNA expression was evaluated for each gene
by Spearman’s rank correlation test. Reported P values are two sided.
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http://www.translational-medicine.com/content/10/1/185the genes differentially methylated between HM and LM
patients (Additional file 2), suggesting that an improved
immune recognition of CM cells with a LM profile might
contribute to the better survival of these patients. Though
this hypothesis has still to be demonstrated and is cur-
rently under investigation, an initial support may come
from the well known involvement of promoter methyla-
tion in regulating the expression of different molecules
involved in the immune recognition of cancer cells, in-
cluding: i) the de novo expression of the Cancer TestisAntigens (CTA) tumor associated antigens by neoplastic
cells of different histotype and melanoma stem cells fol-
lowing promoter hypomethylation; ii) the direct correl-
ation between levels and total number of CTA expressed
in short-term cultures of CM cells and LINE-1 hypo-
methylation (Sigalotti and Maio, unpublished); iii) the abil-
ity of pharmacologic DNA hypomethylation to increase
immunogenicity and immune recognition of cancer cells
through the up-regulation of HLA class I and co-stimula-
tory/accessory molecules [5,19].
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http://www.translational-medicine.com/content/10/1/185Irrespective of the underlying biological features asso-
ciated with the different whole-genome methylation pro-
files, the prognostic value of methylome classification here
identified for stage IIIC CM patients bears several import-
ant practical clinical implications. Among these are: i) pro-
viding an improved clinico-pathological sub-staging; ii)
modulating post-surgery follow-up-procedures; iii) select-
ing patients at higher risk of recurrence for adjuvant treat-
ment(s); iv) stratifying patients in clinical trials based on
their differential prognosis. This latter aspect is of particu-
lar relevance also in view of multiple studies that have
explored new adjuvant regimens in stage III CM patients,
in the US and European cooperative groups. These con-
siderations may not be restricted to CM. Indeed, a recent
work, investigating whole-genome methylation profiles in
breast cancer, demonstrated that the group of patients
with high-methylation tumors disproportionately included
individuals with a poor prognosis defined by the 70-gene
expression prognostic signature of van’t Veer et al. [20].
Conclusions
In conclusion, the data reported in this study present the
first whole-methylome defined prognostic classifier for
advanced operable melanoma of stage IIIC, and suggest
the evaluation of this for the routine clinico-pathological
ascertainment of patients to allow a more accurate assess-
ment of clinical trial results, as well as ultimately to enable
personalized management of patients in the clinical rou-
tine. Whether the methylation classifier presented in this
study will be more easily and effectively translated into the
daily clinical practice than previously identified gene
expression- and microRNA-based prognostic classifiers
[21] is the object of further investigations. Along this line,
we are currently planning a prospective study to inde-
pendently validate our findings and provide the required
support for their feasible transfer into the clinical setting.
Concomitantly, the pathways affected by aberrant methy-
lation are being carefully explored and functionally char-
acterized to possibly provide new therapeutic targets that
could be hit by specific therapeutics, possibly combined
with epigenetic treatments.
Additional files
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Additional file 2: Biological processes significantly over-represented
in genes differentially methylated between HM and LM CM patients.
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